Search

BACKGROUND Hereditary spastic paraplegia presents spasticity as the main clinical manifestation, reducing gait quality and producing incapacity. Management with botulinum toxin type A (BoNT-A) is not well elucidated. The objective of the current study was to evaluate the efficacy and safety of BoNT-A in patients with hereditary spastic paraplegias. METHODS This was a double-blind, randomized, placebo-controlled crossover trial. Each participant was randomly assigned to receive 1 injection session of either BoNT-A (100 IU/2 mL of Prosigne in each adductor magnus and each triceps surae) or saline 0.9% (2 mL). The primary outcome measure was change from baseline in maximal gait velocity, and secondary outcome measures included changes in gait at self-selected velocity, spasticity, muscle strength, Spastic Paraplegia Rating Scale, pain, fatigue, and subjective perception of improvement. We also looked at adverse events reported by the patients. RESULTS We enrolled 55 patients, 36 of whom were men and 41 with the pure phenotype. Mean age was 43 ± 13.4 years (range, 19-72 years), mean age of onset waws 27 ± 13.1 years (range

Background and purpose Neurological manifestations have been identified in the context of autoimmune hepatitis (AIH). Previous case reports highlighted the association between AIH and sensory neuronopathy (SN). Despite that, little is known about the frequency of AIH-related SN and its clinical/neurophysiological profile. Moreover, it is not clear whether SN is an AIH-specific manifestation or related to chronic liver damage. Methods Seventy consecutive AIH patients were enrolled and their characteristics were compared with 52 consecutive patients with chronic active hepatitis B. All subjects underwent clinical and neurophysiological evaluation. Further comparisons were performed between AIH SN and AIH non-SN patients. Results Mean ages and male:female proportions in the AIH and chronic active hepatitis B groups were 42.2 ± 16.3/51.7 ± 13.6 years and 14:56/29:23, respectively. The frequencies of carpal tunnel syndrome, radiculopathy and polyneuropathy were similar between groups. In contrast, SN was identified only in AIH patients (5/70 vs. 0/52, P = 0.04); the overall prevalence of AIH-related SN was 7% with an average profile of a woman in her 40s with asymmetric onset of sensory deficits that chronically evolved to disabling proprioceptive ataxia associated with marked dysautonomia. Neurological disability and hepatocellular damage did not follow in parallel. Anti-fibroblast growth factor receptor type 3 antibodies were found in 3/5 (60%) of the patients with AIH-related SN. Clinical or demographic predictors of SN in the context of AIH could not be identified. Conclusion Sensory neuronopathy, but not other peripheral nervous system diseases, is a specific AIH neurological manifestation. It is often disabling and, in contrast to hepatocellular injury, does not respond to immunosuppression.

Sensory neuronopathies (SN) are a group of peripheral nerve disorders characterized by multifocal non-length-dependent sensory deficits and sensory ataxia. Its recognition is essential not only for proper management but also to guide the etiological investigation. The uncommon SN clinical picture and its rarity set the conditions for the misdiagnosis and the diagnostic delay, especially in non-paraneoplastic SN. Therefore, our objectives were to characterize the diagnostic odyssey for non-paraneoplastic SN patients, as well as to identify possible associated factors. Methods We consecutively enrolled 48 non-paraneoplastic SN patients followed in a tertiary neuromuscular clinic at the University of Campinas (Brazil). All patients were instructed to retrieve their previous medical records, and we collected the data regarding demographics, disease onset, previous incorrect diagnoses made and the recommended treatments. Results There were 34 women, with a mean age at the diagnosis of 45.9 ± 12.2 years, and 28/48 (58%) of the patients were idiopathic. Negative sensory symptoms were the heralding symptoms in 25/48 (52%); these were asymmetric in 36/48 (75%) and followed a chronic course in 35/48 (73%). On average, it took 5.4 ± 5.3 years for SN to be diagnosed; patients had an average of 3.4 ± 1.5 incorrect diagnoses. A disease onset before the age of 40 was associated to shorter diagnosis delay (3.7 ± 3.4 vs. 7.8 ± 6.7 years, p = 0.01). Conclusions These results suggest that diagnostic delay and misdiagnosis are frequent in non-paraneoplastic SN patients. As in other rare conditions, increased awareness in all the healthcare system levels is paramount to ensure accurate diagnosis and to improve care of these patients. RESUMO As neuronopatias sensitivas (NS) representam um grupo de doenças caracterizadas por ataxia sensitiva e déficits sensitivos multifocais e não-comprimento dependentes. O seu reconhecimento é fundamental para o tratamento apropriado e para a investigação de doenças associadas. O quadro clínico pouco frequente aliado à baixa prevalência, especialmente das formas não-paraneoplásicas (NSnp), colaboram para o atraso e erro no diagnóstico. Os objetivos desse trabalho são descrever a odisseia diagnóstica dos pacientes com NSnp e tentar identificar possíveis fatores associados. Métodos Foram incluídos consecutivamente 48 pacientes com NSnp acompanhados no ambulatório de doenças neuromusculares da Universidade Estadual de Campinas (Brasil). Dados demográficos e sobre o início da NS (incluindo diagnósticos que lhes foram dados e tratamentos prescritos) foram coletados. Resultados Na coorte descrita havia 34 mulheres e a idade ao diagnóstico era de 45,9 ± 12,2 anos. Os sintomas inaugurais eram sensitivos deficitários em 25/48 (52%) dos pacientes, sendo assimétricos em 36/48 (75%) e de evolução crônica em 35/48 (73%). Para 28/48 (58%) dos pacientes a NS era idiopática. Em média, os pacientes com NSnp tiveram um atraso diagnóstico de 5,4 ± 5,3 anos com uma média de 3,4 ± 1,5 diagnósticos incorretos. Pacientes com início antes dos 40 anos tiveram diagnóstico mais precoce que aqueles com início tardio (3,7 ± 3,4 vs. 7,8 ± 6,7 anos, p = 0,01). Conclusão Os dados ora apresentados sugerem que o erro e o atraso diagnóstico são frequentes e impactam os pacientes com NS. A importância do diagnóstico das NS deve ser constante em todos os níveis do sistema de saúde para o diagnóstico correto e a consequente melhora no cuidado a esses pacientes.

Many genes associated with familial forms of the amyotrophic lateral sclerosis (fALS) have been identified in European and North American cohorts. However, little is known about the genetic bases of fALS in Latin America and Brazil, in particular. To address this question, we recruited 107 patients with fALS from 93 unrelated families from Southeastern, Southern, and Northeastern regions of the country. A 3-step diagnostic approach was used: 1) Triplet repeat primed polymerase chain reaction to search for C9orf72 expansions, then 2) fragment digestion to search for the c.166 C>T VAPB variant, and finally, 3) whole exome sequencing for those who tested negative. We identified the genetic cause for fALS in 70% of the families. VAPB and C9orf72 were the most frequent genes (30% and 22%, respectively), followed by SOD1, TARDBP, ANXA11, and FUS. Five novel variants in known ALS genes were found, including the SOD1 Val120Leu and ANXA11 Asp40Tyr, which were seen in 2 unrelated families each. In conclusion, VAPB and then C9orf72 are the genes most commonly related to fALS in Brazil.

BackgroundBulbar involvement is a hallmark of amyotrophic lateral sclerosis (ALS), but surprisingly very few studies have addressed the frequency, pattern and clinical relevance of laryngeal involvement in the disease.MethodsTwenty-six patients with spinal-onset ALS underwent nasofibroscopy (NF), followed by laryngeal electromyography (LEMG). We also studied resting activity and motor unit potentials of the genioglossus and masseter muscles.ResultsTwenty-four patients presented neurogenic changes in at least one laryngeal muscle. There were fibrillation and/or fasciculation potentials associated with chronic neurogenic changes in the same muscle in 16 patients; of these, 9 had no alteration in the genioglossus. We found no patient with tongue neurogenic changes and normal LEMG. NF was abnormal in 14 patients; in the remaining 12, LEMG identified neurogenic changes in 11 of them.ConclusionLEMG is able to identify laryngeal denervation in patients with ALS, sometimes before clinical manifestations are noticed. This technique may be a useful diagnostic tool for selected patients with suspicion of ALS.

Little is known about the genetic basis of amyotrophic lateral sclerosis (ALS) outside Europe and US. In this study, we investigated whether intermediate CAG expansions at ATXN1 were associated to ALS in the Brazilian population. To accomplish that, representative samples from 411 unrelated patients and 436 neurologically normal controls from 6 centers spread over the territory were genotyped to quantify ATXN1 expansions. We found that ATXN1 intermediate-length expansion (≥34 CAG repeats) are associated with the disease (odds ratio = 2.19, 95% CI = 1.081–4.441, p = .026). Most ATXN1-positive patients had classical phenotype, but some of them presented predominant lower motor neuron involvement. None of them had associated ataxia. Frontotemporal dementia was concomitantly found in 12.5% of patients carrying the intermediate ATXN1 expansion. Further studies are needed to validate these findings and to understand the pathophysiological mechanisms that connect ataxin-1 and ALS.

Sensory neuronopathies (SN) result from dorsal root ganglia damage and manifest with a combination of sensory deficits and proprioceptive ataxia. Characterization of the natural history and development of therapeutic trials are hampered by the lack of clinical scales that capture the whole spectrum of SN-related manifestations. We propose and validate a rating instrument for SN. Three experienced neuromuscular specialists developed items to rate SN. The resultant instrument was later validated by the assessment of the intra-class correlation coefficient, for inter-rater validity in 48 SN patients, and later in a smaller subset of 16 patients to assess its intra-rater validity. Standardized Crombach's alpha and Oblimin rotation analysis were performed to verify internal consistency and items' relationship, respectively. Evaluation of Sensory Ataxia Rating Scale (SEARS)'s external validity was performed by comparison to: scale for the assessment and rating of ataxia (SARA), Beck balance scale (BBS), and INCAT sensory sum score (ISS). A 10-item scale with an intra-class correlation coefficient >0.95 for intra- and inter-rating measurements with a good internal consistency (standardized Cronbach's alpha of 0.83) were observed. There was a normal distribution of the scores without a floor or ceiling effect. A moderate to good correlation between SEARS and SARA, BBS, and ISS was observed. SEARS is a reliable, easy-to-perform and consistent instrument to rate SN. Larger cohorts and multicenter studies are needed to validate its usefulness towards possible treatment trials.

Sensory neuronopathies (SN) are characterized by asymmetric non-length dependent sensory deficits and sensory ataxia. Autonomic dysfunction in SN was not yet evaluated regarding its frequency, characteristics and relationship to sensory deficits. To address these issues, we performed a comprehensive clinical and neurophysiological evaluation of a large cohort of patients with non-paraneoplastic SN (np-SN).We enrolled 50 consecutive patients with npSN and 32 age/sex-matched healthy controls. They were clinically evaluated (SCOPA-Aut scale) and underwent neurophysiological autonomic assessment (quantitative sudomotor axon reflex test, heart rate variability and sympathetic skin response).Mean age of patients was 50.9 ± 10.3 years and there were 18 men. npSN patients had higher SCOPA-Aut scores than controls (26.63 ± 12.72 vs. 12.66 ± 9.11, p .001). QSART was abnormal in 92% of the patients - sweat volumes in all examined sites were smaller among patients (p .001). Cardiovascular autonomic neuropathy was more frequent in these patients as well (p .001).Altogether our results suggest that autonomic dysfunction in distinct domains is frequent in npSN patients. These findings suggest that the clinical picture of npSN is related to a double neuronopathy: sensory and autonomic.

Background and purpose Friedreich's ataxia (FRDA) is the most common autosomal-recessive ataxia worldwide. It is characterized by early onset, sensory abnormalities and slowly progressive ataxia. All magnetic resonance imaging (MRI)-based studies have focused on the evaluation of adult patients. Therefore, we designed a cross-sectional multimodal MRI-based study to investigate the anatomical substrates involved in the early stages of FRDA. Methods We enrolled 37 patients (12 children) and 38 controls. All subjects underwent MRI in a 3T device to assess gray and white matter. We used measures from FreeSurfer and CERES to evaluate the cerebral and cerebellar cortices. The T1 multiatlas assessed deep gray matter. The diffusion tensor imaging multiatlas was used to investigate microstructural abnormalities in brain white matter and SpineSeg was used to assess the cervical spinal cord. All analyses were corrected for multiple comparisons. Results Comparison with age-matched controls showed that pediatric patients have spinal cord, inferior cerebellar peduncle and red nucleus damage. In contrast, adult patients showed more widespread white matter damage than pediatric patients. With regard to gray matter, we found cortical thinning at the left central sulcus and volumetric reduction in the thalami and hippocampi only in adult patients. Finally, values of fractional anisotropy in adult patients and radial diffusivity in pediatric patients from the inferior cerebellar peduncle correlated with disease duration and ataxia severity, respectively. Conclusions Structural damage in FRDA begins in the spinal cord and inferior cerebellar peduncle as well as the red nucleus, and progresses to cerebral areas in adulthood. These results shed some light on the early stages of FRDA and highlight potential neuroimaging markers for therapeutic trials.

The cranial nerves IX and X emerge from medulla oblongata and have motor, sensory, and parasympathetic functions. Some of these are amenable to neurophysiological assessment. It is often hard to separate the individual contribution of each nerve; in fact, some of the techniques are indeed a composite functional measure of both nerves. The main methods are the evaluation of the swallowing function (combined IX and X), laryngeal electromyogram (predominant motor vagal function), and heart rate variability (predominant parasympathetic vagal function). This review describes, therefore, the techniques that best evaluate the major symptoms presented in IX and X cranial nerve disturbance: dysphagia, dysphonia, and autonomic parasympathetic dysfunction.

SPG11 mutations are the major cause of autosomal recessive Hereditary Spastic Paraplegia. The disease has a wide phenotypic variability indicating many regions of the nervous system besides the corticospinal tract are affected. Despite this, anatomical and phenotypic characterization is restricted. In the present study, we investigate the anatomical abnormalities related to SPG11 mutations and how they relate to clinical and cognitive measures. Moreover, we aim to depict how the disease course influences the regions affected, unraveling different susceptibility of specific neuronal populations. We performed clinical and paraclinical studies encompassing neuropsychological, neuroimaging, and neurophysiological tools in a cohort of twenty-five patients and age matched controls. We assessed cortical thickness (FreeSurfer software), deep grey matter volumes (T1-MultiAtlas tool), white matter microstructural damage (DTI-MultiAtlas) and spinal cord morphometry (Spineseg software) on a 3 T MRI scan. Mean age and disease duration were 29 and 13.2 years respectively. Sixty-four percent of the patients were wheelchair bound while 84% were demented. We were able to unfold a diffuse pattern of white matter integrity loss as well as basal ganglia and spinal cord atrophy. Such findings contrasted with a restricted pattern of cortical thinning (motor, limbic and parietal cortices). Electromyography revealed motor neuronopathy affecting 96% of the probands. Correlations with disease duration pointed towards a progressive degeneration of multiple grey matter structures and spinal cord, but not of the white matter. SPG11-related hereditary spastic paraplegia is characterized by selective neuronal vulnerability, in which a precocious and widespread white matter involvement is later followed by a restricted but clearly progressive grey matter degeneration., Highlights • SPG11 leads to widespread White matter (WM) and deep grey matter (GM) damage. • Cortical thinning is restricted to motor, limbic and parietal regions. • Motor Cortex thinning as well as Spinal Cord and basal ganglia atrophy correlate with motor handicap and disease duration. • WM and thalamic damage correlate with cognitive impairment. • Progressive damage of GM contrasts with an apparently static WM involvement.

Introduction Electromyography (EMG) is a useful ancillary test in the diagnosis of neuromuscular disorders. EMG patterns may be helpful to identify specific subtypes of inherited muscle disease. There are few studies looking at the EMG profile in congenital myopathies, and centronuclear myopathy (CNM) in particular. The objective of this study is to describe clinical and EMG findings in patients with CNM from a tertiary Brazilian university hospital. Methods We selected all patients with pathological confirmation (muscle biopsy) of CNM and regularly followed at UNICAMP (State University of Campinas), from 2016 to 2017. Individuals with X-linked CNM were not included. For each patient, we reviewed nerve conduction studies (NCS) and EMG findings at rest and during contraction of upper and lower limbs. We looked specifically at the presence of myotonic discharges. The total score of motor function measure scale (MFM32) was employed as a clinical examination marker of disease severity. Results Eleven patients were enrolled in this study. There were six children, seven females, mean age 18.1 years when first examined in our service; a boy with 4-years-old, was the youngest and a 54-year-old lady was the oldest. The mean/median of MFM32 total score was 65.0%.The motor and sensory NCS were normal for all nerves tested. Regarding EMG and the occurrence of abnormal spontaneous activity: the myotonic discharges, when present, predominated in distal muscles: tibialis anterior and abductor pollicis brevis, and all occurred at rest. During activation, all muscles presented short duration and polyphasic motor unit action potentials without proximal or distal preferential involvement. None of the patients had clinical myotonia (either percussion or action), but electrical myotonia was found in 6 out of the 11 patients (54%). Five women and one men had clinical phenotype similar to juvenile or classical Steinert disease (DM1). Two patients had negative genetic test for the disease, and in one of the was found a mutation in the DNM2 gene. We do highlight that two patients were followed up for decades as DM1 until properly diagnosed as CNM at our hospital. Conclusion CNM must be included in the differential diagnosis of a patient with electrical, but not clinical myotonia. Clinical neurophysiologists must be aware of this profile to assist in the recognition of CNM. The frequency of abnormal spontaneous activity at EMG is similar to other studies.

Introduction Amyotrophic Lateral Sclerosis (ALS) is the most relevant motor neuron disease in adults and characterized by widespread weakness. Despite frequent bulbar involvement, little is known about clinical and electrophysiological changes in the larynx in patients with ALS. The objective of this study was to evaluate the frequency and pattern of involvement of laryngeal muscles in ALS and its functional relevance. In addition, we assessed whether laryngeal EMG (LEMG) would increase the diagnostic sensitivity for ALS. Methods Fourteen ALS patients, 13 with spinal onset and 1 with bulbar onset, underwent nasofibroscopy (NF) followed by LEMG, in which a concentric needle was used to evaluate the thyroid-arytenoid (TA), lateral crico-arytenoid (CAL), posterior crico-arytenoid (CAP) and crico-thyroid (CT) muscles, at rest and during activation. After LEMG, resting and activation of the genioglossus and masseter muscles were also studied using the same concentric needle. Results The mean age of the patients was 48.5 years and there were 6 women. The procedures were fast (30 min on average) and uneventful. Thirteen patients presented neurogenic changes in at least one laryngeal muscle. A single patient had entirely normal LEMG. We found a pattern compatible with chronic denervation (MUAPs remodeling and incomplete recruitment) with the following frequency: TA muscle in 11/14 patients (78.5%); CT in 10/14 patients (71.4%); CAP in 10/14 patients (71.4%) and CAL in 7/14 patients (50%). In 8 patients, there were fibrillations and/ or fasciculations associated with chronic neurogenic changes in the same muscle; of these, 4 had no alteration in the genioglossus muscle and 2 had only chronic alterations in the same muscle. NF revealed motor abnormalities in the larynx in 9 patients; in the remaining 5, NF was normal but LEMG identified signs of denervation in 4 of them. Conclusion LEMG is able to identify laryngeal denervation in patients with ALS. This procedure may increase diagnostic sensitivity for ALS by identifying bulbar involvement in patients without tongue denervation. Changes in LEMG may precede clinical involvement of the larynx in these patients.

Introduction Sensory neuronopathies (SN) are a distinct group of peripheral nerve disorders that emerge from the dorsal root ganglia damage. The resultant phenotype is characterized by multifocal non-length dependent sensory deficits. This pattern of sensory impairment produces a sensory symptoms spectrum with different combinations of sensory ataxia and pain. Neuropathic pain (NP) is often present in the context of SN, however its description and its impact on SN diagnosis delay have not been previously addressed. Objective To describe neuropathic pain in SN patients and to evaluate its impact on the diagnosis delay of these patients. Methods We evaluated 40 consecutive patients with SN who were regularly followed in a tertiary neuromuscular clinic. For each patient, we obtained data regarding the presence of pain, the Leeds assessment of neuropathic symptoms and signs (LANSS) score was obtained and all patients were actively interrogated regarding the onset of the SN symptoms, previous diagnoses for which they were eventually treated, the number and the specialty of previous physicians consulted. Non-parametric tests were used and p values Results The mean age of SN patients was 50.9 ± 11.3 years and there were 30 women. For 33 SN patients pain was part of the clinical picture and for22 of those, the pain was described as neuropathic accordingly to LANSS (LANSS scores ⩾ 12). None of these patients was first evaluated in our center by the time of the settlement of SN symptoms. Every patient was evaluated by a mean of 4.32 ± 2.21 specialists and received a mean of 3.1 ± 1.4 wrong different diagnoses. The mean time between the SN symptoms onset and the proper SN diagnosis was 5.47 ± 5.3 years. Considering those patients with and without NP the mean time to the SN diagnose was 7.13 ± 6.3 and 3.44 ± 2.7 years (p = 0.026) respectively. Conclusion These results suggest that pain, specially the NP, is a common feature in SN and may impose a significant delay for its correct diagnosis.